Cargando…
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
BACKGROUND: Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends to be a progressive disease, and most patien...
Autores principales: | Clar, Christine, Gill, James Alexander, Court, Rachel, Waugh, Norman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488745/ https://www.ncbi.nlm.nih.gov/pubmed/23087012 http://dx.doi.org/10.1136/bmjopen-2012-001007 |
Ejemplares similares
-
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2016) -
Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review
por: González-González, José Gerardo, et al.
Publicado: (2021) -
Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol
por: Dorsey-Treviño, Edgar Gerardo, et al.
Publicado: (2018) -
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015) -
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)